Aurinia Pharmaceuticals Stock Options
| AUPH Stock | USD 7.95 0.05 0.62% |
Aurinia Pharmaceuticals' latest option contracts expiring on April 17th 2025 are carrying combined implied volatility of 1.28 with a put-to-call open interest ratio of 0.13 over 27 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on April 17th 2025. The total put volume is at 5.0, with calls trading at the volume of 2.9 K. This yields a 0.0 put-to-call volume ratio.
Open Interest Against April 17th 2025 Option Contracts
2025-04-17
The chart above shows Aurinia Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Aurinia Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Aurinia Pharmaceuticals' option, there is no secondary market available for investors to trade.
Aurinia Pharmaceuticals Maximum Pain Price Across 2025-04-17 Option Contracts
Aurinia Pharmaceuticals' max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Aurinia Pharmaceuticals
Analyzing Aurinia Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in Aurinia Pharmaceuticals regardless of its overall volatility. This is especially true when Aurinia Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Aurinia Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Aurinia Pharmaceuticals' stock while costing only a fraction of its price.
Aurinia Pharmaceuticals In The Money Call Balance
When Aurinia Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Aurinia Pharmaceuticals stock is said to be in the money. When it comes to buying Aurinia Pharmaceuticals' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Aurinia Pharmaceuticals are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Aurinia Current Options Market Mood
Aurinia Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Aurinia Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Aurinia Pharmaceuticals' options investors are not very successful. Aurinia Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Aurinia contract
Base on the Rule 16, the options market is currently suggesting that Aurinia Pharmaceuticals will have an average daily up or down price movement of about 0.08% per day over the life of the 2025-04-17 option contract. With Aurinia Pharmaceuticals trading at USD 7.95, that is roughly USD 0.00636. If you think that the market is fully incorporating Aurinia Pharmaceuticals' daily price movement you should consider buying Aurinia Pharmaceuticals options at the current volatility level of 1.28%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Aurinia |
Purchasing Aurinia Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Aurinia calls. Remember, the seller must deliver Aurinia Pharmaceuticals stock to the call owner when a call is exercised.
Aurinia Pharmaceuticals Option Chain
When Aurinia Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Aurinia Pharmaceuticals stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Aurinia Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on Aurinia. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Aurinia. It also shows strike prices and maturity days for a Aurinia Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | AUPH250417C00004000 | 12 | 4.0 | 1.75 - 6.0 | 5.6 | In |
Call | AUPH250417C00005000 | 19 | 5.0 | 0.55 - 4.9 | 5.5 | In |
Call | AUPH250417C00006000 | 186 | 6.0 | 1.8 - 2.7 | 2.27 | In |
Call | AUPH250417C00007000 | 907 | 7.0 | 1.35 - 3.3 | 1.75 | In |
Call | AUPH250417C00008000 | 631 | 8.0 | 0.45 - 1.45 | 1.0 | Out |
Call | AUPH250417C00009000 | 1139 | 9.0 | 0.5 - 1.1 | 0.96 | Out |
Call | AUPH250417C00010000 | 5466 | 10.0 | 0.5 - 0.6 | 0.63 | Out |
Call | AUPH250417C00011000 | 1007 | 11.0 | 0.3 - 0.7 | 0.3 | Out |
Call | AUPH250417C00012000 | 7691 | 12.0 | 0.3 - 0.35 | 0.3 | Out |
Call | AUPH250417C00013000 | 101 | 13.0 | 0.0 - 0.35 | 0.15 | Out |
Call | AUPH250417C00014000 | 0 | 14.0 | 0.0 - 0.75 | 0.75 | |
Call | AUPH250417C00015000 | 865 | 15.0 | 0.0 - 0.15 | 0.15 | Out |
Call | AUPH250417C00020000 | 34 | 20.0 | 0.0 - 0.5 | 0.07 | Out |
Put | AUPH250417P00003000 | 11 | 3.0 | 0.0 - 0.5 | 0.25 | Out |
Put | AUPH250417P00004000 | 31 | 4.0 | 0.0 - 0.5 | 0.2 | Out |
Put | AUPH250417P00005000 | 4 | 5.0 | 0.0 - 1.1 | 0.3 | Out |
Put | AUPH250417P00006000 | 506 | 6.0 | 0.0 - 3.9 | 0.04 | Out |
Put | AUPH250417P00007000 | 1092 | 7.0 | 0.55 - 0.9 | 0.4 | Out |
Put | AUPH250417P00008000 | 315 | 8.0 | 1.0 - 1.35 | 0.95 | Out |
Put | AUPH250417P00009000 | 196 | 9.0 | 1.65 - 2.05 | 1.2 | In |
Put | AUPH250417P00010000 | 118 | 10.0 | 1.85 - 2.8 | 2.63 | In |
Put | AUPH250417P00011000 | 49 | 11.0 | 2.75 - 3.6 | 1.83 | In |
Put | AUPH250417P00012000 | 5 | 12.0 | 3.6 - 4.5 | 2.54 | In |
Put | AUPH250417P00013000 | 0 | 13.0 | 2.6 - 7.1 | 2.6 | In |
Put | AUPH250417P00014000 | 0 | 14.0 | 4.6 - 8.0 | 4.6 | In |
Put | AUPH250417P00015000 | 1 | 15.0 | 6.4 - 8.7 | 5.86 | In |
Put | AUPH250417P00020000 | 0 | 20.0 | 10.7 - 14.2 | 10.7 | In |
Aurinia Total Stockholder Equity
Total Stockholder Equity |
|
Aurinia Pharmaceuticals Corporate Management
| Chris Hays | VP Marketing | Profile | |
| Premchandran Ramiya | Senior Chain | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Ann Daus | Senior Quality | Profile | |
| Andrea Christopher | Head Relations | Profile | |
| Michael Martin | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share | Quarterly Revenue Growth 0.243 | Return On Assets | Return On Equity |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.